JP2010520226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520226A5 JP2010520226A5 JP2009551878A JP2009551878A JP2010520226A5 JP 2010520226 A5 JP2010520226 A5 JP 2010520226A5 JP 2009551878 A JP2009551878 A JP 2009551878A JP 2009551878 A JP2009551878 A JP 2009551878A JP 2010520226 A5 JP2010520226 A5 JP 2010520226A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- active ingredient
- agent
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 67
- 238000000034 method Methods 0.000 claims 16
- 239000004480 active ingredient Substances 0.000 claims 14
- 239000008188 pellet Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 229940069428 antacid Drugs 0.000 claims 10
- 239000003159 antacid agent Substances 0.000 claims 10
- 239000002552 dosage form Substances 0.000 claims 10
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- 229920000881 Modified starch Polymers 0.000 claims 6
- 230000001458 anti-acid effect Effects 0.000 claims 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 4
- 230000000202 analgesic effect Effects 0.000 claims 4
- 239000003443 antiviral agent Substances 0.000 claims 4
- 235000015872 dietary supplement Nutrition 0.000 claims 4
- -1 tethromycin Chemical compound 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 229960005475 antiinfective agent Drugs 0.000 claims 3
- 238000004090 dissolution Methods 0.000 claims 3
- 229940127022 high-dose drug Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 239000011777 magnesium Substances 0.000 claims 3
- 229910052749 magnesium Inorganic materials 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims 2
- 229960004150 aciclovir Drugs 0.000 claims 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 239000003630 growth substance Substances 0.000 claims 2
- 229940060367 inert ingredients Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims 2
- 229960004089 tigecycline Drugs 0.000 claims 2
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 claims 2
- 229940001496 tribasic sodium phosphate Drugs 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 2
- 229940093257 valacyclovir Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- XUNYDVLIZWUPAW-UHFFFAOYSA-N (4-chlorophenyl) n-(4-methylphenyl)sulfonylcarbamate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)OC1=CC=C(Cl)C=C1 XUNYDVLIZWUPAW-UHFFFAOYSA-N 0.000 claims 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 1
- 239000005893 Diflubenzuron Substances 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000005927 Pyriproxyfen Substances 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 229960002669 albendazole Drugs 0.000 claims 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 1
- 229960003022 amoxicillin Drugs 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- 229940124339 anthelmintic agent Drugs 0.000 claims 1
- 239000000921 anthelmintic agent Substances 0.000 claims 1
- 230000002365 anti-tubercular Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 229940033495 antimalarials Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229960003159 atovaquone Drugs 0.000 claims 1
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000004888 barrier function Effects 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960003184 carprofen Drugs 0.000 claims 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 229960003077 cycloserine Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- 229940019503 diflubenzuron Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960000573 eprosartan mesylate Drugs 0.000 claims 1
- DJSLTDBPKHORNY-XMMWENQYSA-N eprosartan methanesulfonate Chemical compound CS(O)(=O)=O.C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 DJSLTDBPKHORNY-XMMWENQYSA-N 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 229960005473 fenbendazole Drugs 0.000 claims 1
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 229960005102 foscarnet Drugs 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 229960002146 guaifenesin Drugs 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims 1
- FYQGBXGJFWXIPP-UHFFFAOYSA-N hydroprene Chemical compound CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C FYQGBXGJFWXIPP-UHFFFAOYSA-N 0.000 claims 1
- 229930000073 hydroprene Natural products 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000003835 ketolide antibiotic agent Substances 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims 1
- 229960003907 linezolid Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 1
- 229960000884 nelfinavir Drugs 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 150000002960 penicillins Chemical class 0.000 claims 1
- 229960000482 pethidine Drugs 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 229940094035 potassium bromide Drugs 0.000 claims 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims 1
- 229960000611 pyrimethamine Drugs 0.000 claims 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- 229960005224 roxithromycin Drugs 0.000 claims 1
- 150000003873 salicylate salts Chemical class 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960004291 sucralfate Drugs 0.000 claims 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 1
- 229960001017 tolmetin Drugs 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- KYLIMUJRJDIPPF-UHFFFAOYSA-N trisalicylate Chemical compound O=C1OC2=CC=CC=C2C(=O)OC2=CC=CC=C2C(=O)OC2=CC=CC=C12 KYLIMUJRJDIPPF-UHFFFAOYSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
- 229960001661 ursodiol Drugs 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
- 229960005332 zileuton Drugs 0.000 claims 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90445607P | 2007-03-02 | 2007-03-02 | |
| US60/904,456 | 2007-03-02 | ||
| PCT/US2008/055534 WO2008109462A2 (en) | 2007-03-02 | 2008-02-29 | Sustained release pellets comprising wax-like material |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013231841A Division JP2014055158A (ja) | 2007-03-02 | 2013-11-08 | ロウ様物質を用いた徐放性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010520226A JP2010520226A (ja) | 2010-06-10 |
| JP2010520226A5 true JP2010520226A5 (https=) | 2011-03-10 |
| JP5452236B2 JP5452236B2 (ja) | 2014-03-26 |
Family
ID=39649304
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551878A Expired - Fee Related JP5452236B2 (ja) | 2007-03-02 | 2008-02-29 | ロウ様物質を用いた徐放性組成物 |
| JP2013231841A Pending JP2014055158A (ja) | 2007-03-02 | 2013-11-08 | ロウ様物質を用いた徐放性組成物 |
| JP2015117498A Pending JP2016000728A (ja) | 2007-03-02 | 2015-06-10 | ロウ様物質を用いた徐放性組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013231841A Pending JP2014055158A (ja) | 2007-03-02 | 2013-11-08 | ロウ様物質を用いた徐放性組成物 |
| JP2015117498A Pending JP2016000728A (ja) | 2007-03-02 | 2015-06-10 | ロウ様物質を用いた徐放性組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10888521B2 (https=) |
| EP (1) | EP2144599B1 (https=) |
| JP (3) | JP5452236B2 (https=) |
| CN (1) | CN101652128B (https=) |
| AT (1) | ATE476176T1 (https=) |
| AU (1) | AU2008223091B2 (https=) |
| CA (1) | CA2678367C (https=) |
| DE (1) | DE602008002073D1 (https=) |
| ES (1) | ES2350029T3 (https=) |
| WO (1) | WO2008109462A2 (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| ITPD20070274A1 (it) * | 2007-08-08 | 2009-02-09 | Sanypet S P A | Crocchetta per animali e metodo per la sua produzione |
| CA2713128C (en) | 2008-01-25 | 2016-04-05 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| AU2009243681B2 (en) | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| CN102639118B (zh) | 2009-07-22 | 2015-07-29 | 格吕伦塔尔有限公司 | 氧化稳定的抗干扰剂型 |
| KR101738369B1 (ko) | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | 핫 멜트 압출된 제어 방출 투여형 |
| WO2011080570A2 (en) * | 2009-12-29 | 2011-07-07 | Micro Labs Limited | Extended release pharmaceutical composition comprising linezolid and process for preparing the same |
| ES2606227T3 (es) | 2010-02-03 | 2017-03-23 | Grünenthal GmbH | Preparación de una composición farmacéutica en polvo mediante una extrusora |
| IT1398321B1 (it) * | 2010-02-26 | 2013-02-22 | Formevet Spa Ora Formevet Srl | Associazione tra un analgesico ad azione centrale e un antinfiammatorio inibitore selettivo della cicloossigenasi 2 per il trattamento dell'infiammazione e del dolore in campo veterinario |
| TWI516286B (zh) | 2010-09-02 | 2016-01-11 | 歌林達股份有限公司 | 含陰離子聚合物之抗破碎劑型 |
| BR112013005194A2 (pt) | 2010-09-02 | 2016-05-03 | Gruenenthal Gmbh | forma de dosagem resistente à violação compreendendo sal inorgânico |
| US20120107393A1 (en) * | 2010-10-29 | 2012-05-03 | University Of Tennessee Research Foundation | Pellets for Delivery of Biologically Active Substances |
| ES2687027T3 (es) | 2010-11-04 | 2018-10-23 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepáticas |
| EA201400172A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
| BR112014001091A2 (pt) | 2011-07-29 | 2017-02-14 | Gruenenthal Gmbh | comprimido resistente à adulteração que fornece liberação imediata do fármaco |
| CN102440963A (zh) * | 2011-11-29 | 2012-05-09 | 北京科信必成医药科技发展有限公司 | 一种别嘌醇缓释微丸及其制备方法 |
| US10722458B2 (en) | 2011-12-02 | 2020-07-28 | Pegasus Laboratories, Inc. | Amphipathic lipid-based sustained release compositions |
| JP2015500241A (ja) * | 2011-12-02 | 2015-01-05 | ペガサス ラボラトリーズ インコーポレイテッド | 両親媒性脂質をベースとする徐放性組成物 |
| CN102716090B (zh) * | 2012-01-05 | 2014-07-16 | 金陵药业股份有限公司 | 一种盐酸二甲双胍缓释微丸及其制备方法 |
| CN102590410A (zh) * | 2012-01-13 | 2012-07-18 | 亚宝药业太原制药有限公司 | 盐酸氨基葡萄糖胶囊的含量测定方法 |
| CN102579405A (zh) * | 2012-01-17 | 2012-07-18 | 广州科的信医药技术有限公司 | 一种盐酸噻氯匹定缓释胶囊及其制备方法 |
| PL2811833T3 (pl) | 2012-02-06 | 2016-05-31 | William L Pridgen | Połączenie famcyklowiru i celekoksybu na czynnościowe zespoły somatyczne |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| EP2838512B1 (en) | 2012-04-18 | 2018-08-22 | Grünenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| EP2846773A4 (en) | 2012-05-10 | 2015-12-30 | Painreform Ltd | DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| CN102743341B (zh) * | 2012-07-28 | 2014-02-26 | 西安德天药业股份有限公司 | 右旋酮洛芬氨丁三醇缓释微粒及其制备方法和缓释制剂 |
| CN103860551A (zh) * | 2012-12-10 | 2014-06-18 | 鲁南制药集团股份有限公司 | 含有依托度酸和盐酸曲马多的药物组合物及其应用 |
| EP3003279A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| WO2014207769A1 (en) | 2013-06-27 | 2014-12-31 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| BR112016000194A8 (pt) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
| CN103432082A (zh) * | 2013-08-29 | 2013-12-11 | 江苏正大清江制药有限公司 | 氨基葡萄糖组合物及其制备方法 |
| EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| WO2015153984A2 (en) | 2014-04-04 | 2015-10-08 | Pharmaquest International Center, LLC | Disintegrating monolithic modified release tablets containing quadri-layer extended release granules |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| MA41124A (fr) * | 2014-12-05 | 2017-10-10 | Sun Pharmaceutical Ind Ltd | Compositions en suspension à libération prolongée à rétention gastrique |
| CN105982860B (zh) * | 2015-02-11 | 2020-04-14 | 北京科信必成医药科技发展有限公司 | 愈创甘油醚无水吞服掩味颗粒 |
| WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| CN108601739B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 考来烯胺丸剂及其制备方法 |
| JP2019523275A (ja) * | 2016-07-26 | 2019-08-22 | アナンド パラチュル，ヴィヴェク | 有効成分の徐放性組成物 |
| US10137111B2 (en) | 2016-08-11 | 2018-11-27 | Adamis Pharmaceuticals Corporation | Drug compositions comprising an anti-parasitic and proton pump inhibitor |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| EP3459527B1 (en) | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| CN107802610B (zh) * | 2017-11-22 | 2020-10-20 | 乐普药业股份有限公司 | 一种单硝酸异山梨酯缓释片及制备方法 |
| WO2019113493A1 (en) | 2017-12-08 | 2019-06-13 | Adamis Pharmaceuticals Corporation | Drug compositions |
| CN111542300B (zh) | 2017-12-29 | 2023-03-28 | 联合利华知识产权控股有限公司 | 非球形微囊 |
| MX386185B (es) | 2017-12-29 | 2025-03-18 | Unilever Ip Holdings B V | Microcápsula no esférica. |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| PL3810581T3 (pl) | 2018-06-20 | 2025-04-28 | Albireo Ab | Modyfikacje kryształu odewiksibatu |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| CN108578376A (zh) * | 2018-07-27 | 2018-09-28 | 广州柏赛罗药业有限公司 | 性能改善的缓释微丸组合物 |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| JP7603000B2 (ja) * | 2018-08-31 | 2024-12-19 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンｄ小児用剤形、製造方法および使用方法 |
| TWI835997B (zh) | 2019-02-06 | 2024-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其用作膽酸調節劑之用途 |
| CN118852054A (zh) | 2019-02-06 | 2024-10-29 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| IT201900013449A1 (it) * | 2019-07-31 | 2021-01-31 | Vetagro Int S R L | Composizione comprendente amminoacidi e una matrice lipidica per animali monogastrici non mammiferi e suo uso |
| IT201900013473A1 (it) * | 2019-07-31 | 2021-01-31 | Vetagro Int S R L | Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale |
| CN110917144A (zh) * | 2019-11-30 | 2020-03-27 | 江苏艾兰得营养品有限公司 | 一种骨架型维生素c缓释微丸及其制备方法 |
| IL293379B2 (en) | 2019-12-04 | 2026-04-01 | Albireo Ab | Benzothia(dia)azepine compounds and their use as bile acid modulators |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| EP4069247B1 (en) | 2019-12-04 | 2025-03-26 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN110898036A (zh) * | 2019-12-18 | 2020-03-24 | 乐普制药科技有限公司 | 一种熊去氧胆酸缓释肠溶胶囊及其制备方法 |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| GB2618161A (en) * | 2020-12-25 | 2023-11-01 | Nutriventia Ltd | Stable prolonged release formulation of vitamin C and A process for preparation thereof |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CN113791150B (zh) * | 2021-09-09 | 2023-08-11 | 浙江公正检验中心有限公司 | 一种用于动物源性食品中头孢类药物残留量的检测方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3908028A (en) * | 1973-04-19 | 1975-09-23 | Procter & Gamble | Soft drink composition containing paramethoxycinnamaldehyde as a flavoring agent and sweetner |
| US4166107A (en) * | 1978-07-25 | 1979-08-28 | The United States Of America As Represented By The Secretary Of Agriculture | Sustained release bolus formulations containing insect growth regulators for control of livestock pests |
| IT1227336B (it) | 1987-09-11 | 1991-04-08 | Squibb & Sons Inc | Composizione farmaceutica contenente un carico elevato di medicamento e procedimento per la sua preparazione |
| US4761450A (en) * | 1987-12-11 | 1988-08-02 | Baychem International, Inc. | Compatible polymer blends useful as melt adhesives |
| JP2760012B2 (ja) * | 1988-12-26 | 1998-05-28 | 武田薬品工業株式会社 | 持続性細粒剤 |
| JPH02193914A (ja) | 1989-01-23 | 1990-07-31 | Sumitomo Pharmaceut Co Ltd | マトリックス型持続性製剤 |
| GB8913889D0 (en) * | 1989-06-16 | 1989-08-02 | May & Baker Ltd | New compositions of matter |
| RU2111663C1 (ru) * | 1991-01-16 | 1998-05-27 | Фмк Корпорейшн | Твердая сыпучая композиция носителя для активного вещества в твердой дозированной вододиспергируемой форме, способ ее получения и твердая дозированная форма |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| ES2150438T3 (es) * | 1991-12-30 | 2000-12-01 | Fmc Corp | Composicion de esferonizacion a base de celulosa microcristalina. |
| SE9200858L (sv) * | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Metod för framställning av pellets med fördröjd frisättning |
| US5700485A (en) | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
| NZ260408A (en) * | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| US5582351A (en) * | 1993-08-09 | 1996-12-10 | Tsau; Josef | Convenient to use aspartame and method of making |
| JP3776941B2 (ja) * | 1993-12-24 | 2006-05-24 | 塩野義製薬株式会社 | 味覚の改善された顆粒剤及びその製造方法 |
| DE4413350A1 (de) * | 1994-04-18 | 1995-10-19 | Basf Ag | Retard-Matrixpellets und Verfahren zu ihrer Herstellung |
| US5582855A (en) * | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
| DK0812195T3 (da) * | 1995-02-28 | 2003-03-03 | Aventis Pharma Inc | Farmaceutisk sammensætning til piperidinoalkanolforbindelser |
| FR2742659B1 (fr) | 1995-12-22 | 1998-03-13 | Pf Medicament | Procede de fabrication de minispheres matricielles a liberation prolongee |
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
| CA2241896A1 (en) | 1996-11-01 | 1998-05-14 | Ze'ev Shaked | Sustained release formulation containing dfmo |
| WO1998042311A1 (en) * | 1997-03-25 | 1998-10-01 | Takeda Chemical Industries, Ltd. | Gastrointestinal mucosa-adherent pharmaceutical composition |
| CZ20011629A3 (cs) * | 1998-11-12 | 2001-12-12 | Smithkline Beecham Plc | Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků |
| US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| AP2002002410A0 (en) * | 1999-08-04 | 2002-03-31 | Ranbaxy Laboratories Ltd | Hydrodynamically Balancing Oral Drug Delivery System |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6953593B2 (en) * | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
| HU229705B1 (en) * | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
| US20020086070A1 (en) * | 2000-03-11 | 2002-07-04 | Kuhrts Eric Hauser | Anti-inflammatory and connective tissue repair formulations |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| WO2002005800A2 (en) * | 2000-07-17 | 2002-01-24 | Guilford Pharmaceuticals, Inc. | Compositions for sustained release of analgesic agents, and methods of making and using the same |
| WO2002035991A2 (en) * | 2000-10-30 | 2002-05-10 | The Board Of Regents, The University Of Texas System | Spherical particles produced by a hot-melt extrusion/spheronization process |
| US6620611B2 (en) * | 2001-01-06 | 2003-09-16 | Geovation Technologies, Inc. | Solid-chemical composition for sustained release of organic substrates and complex inorganic phosphates for bioremediation |
| US6897205B2 (en) * | 2001-01-31 | 2005-05-24 | Roehm Gmbh & Co. Kg | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| US6669955B2 (en) | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| ES2292848T3 (es) | 2001-10-12 | 2008-03-16 | Elan Pharma International Limited | Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada. |
| JP2004024686A (ja) | 2002-06-27 | 2004-01-29 | Nippon Shinyaku Co Ltd | 医薬ワックスマトリックスの製法 |
| US20060153908A1 (en) * | 2002-06-27 | 2006-07-13 | Brian Strong | Spherical pellet formulations |
| CN1201736C (zh) * | 2002-07-19 | 2005-05-18 | 安徽省药物研究所 | 甲硝唑结肠定位缓释制剂 |
| US20040208936A1 (en) * | 2002-07-22 | 2004-10-21 | Roland Chorin | Novel compositions |
| TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
| US20050048118A1 (en) * | 2003-07-25 | 2005-03-03 | Joan Cucala Escoi | Modified release venlafaxine hydrochloride tablets |
| DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| WO2005055972A2 (en) * | 2003-12-09 | 2005-06-23 | Nanon A/S | A drug delivery device and a method of producing it |
| US8715724B2 (en) * | 2004-10-29 | 2014-05-06 | Mayne Pharma International Pty Ltd | Tabletting process |
-
2008
- 2008-02-29 AT AT08743631T patent/ATE476176T1/de not_active IP Right Cessation
- 2008-02-29 DE DE602008002073T patent/DE602008002073D1/de active Active
- 2008-02-29 CA CA2678367A patent/CA2678367C/en active Active
- 2008-02-29 JP JP2009551878A patent/JP5452236B2/ja not_active Expired - Fee Related
- 2008-02-29 US US12/040,443 patent/US10888521B2/en active Active
- 2008-02-29 EP EP08743631A patent/EP2144599B1/en not_active Not-in-force
- 2008-02-29 CN CN2008800068721A patent/CN101652128B/zh not_active Expired - Fee Related
- 2008-02-29 WO PCT/US2008/055534 patent/WO2008109462A2/en not_active Ceased
- 2008-02-29 ES ES08743631T patent/ES2350029T3/es active Active
- 2008-02-29 AU AU2008223091A patent/AU2008223091B2/en not_active Ceased
-
2013
- 2013-11-08 JP JP2013231841A patent/JP2014055158A/ja active Pending
-
2015
- 2015-06-10 JP JP2015117498A patent/JP2016000728A/ja active Pending
-
2020
- 2020-12-18 US US17/126,748 patent/US20210113469A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520226A5 (https=) | ||
| JP5452236B2 (ja) | ロウ様物質を用いた徐放性組成物 | |
| US9248096B2 (en) | Amphipathic lipid-based sustained release compositions | |
| ES2683864T3 (es) | Composiciones de corticosteroides administradas oralmente | |
| ES3041483T3 (en) | Pulsatile drug delivery system for treating morning akinesia | |
| ES2673286T3 (es) | Formulaciones multiparticuladas de L-mentol y métodos relacionados | |
| MD4180C1 (ro) | Procedeu de fabricare a compoziţiilor farmaceutice cu conţinut de rifaximină sub formă de microgranule gastrorezistente, compoziţii şi utilizarea lor în tratamentul afecţiunilor inflamatoare ale intestinelor | |
| JP2011504491A (ja) | プレガバリンの制御放出医薬組成物 | |
| RU2011133020A (ru) | Фармацевтические суспензии двойного высвобождения | |
| CN103648485A (zh) | 罗苏伐他汀钙的药物组合物 | |
| WO2012173581A1 (en) | Thiocolchicoside, etodolac and famotidine combinations | |
| CN101677951A (zh) | 三尖杉碱口服剂型 | |
| JP6015116B2 (ja) | 錠剤及びその製造方法 | |
| AU2021204247A1 (en) | Pharmaceutical matrix formulations comprising dimethyl fumarate | |
| JP2008517988A5 (https=) | ||
| WO2017026950A1 (en) | Controlled release propiverine formulations | |
| CN104856971B (zh) | 一种脉冲双释放制剂及其制备方法与应用 | |
| US10722458B2 (en) | Amphipathic lipid-based sustained release compositions | |
| TR201820616A2 (tr) | İBUPROFEN, PSÖDOEFEDRİN, ASKORBİK ASİT ve PROPOLİS İÇEREN BİR FARMASÖTİK BİLEŞİM | |
| WO2017115745A1 (ja) | 圧縮成型製剤 |